BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.36
-0.30 (-3.11%)
At close: Jun 27, 2025, 4:00 PM
9.54
+0.18 (1.92%)
After-hours: Jun 27, 2025, 7:51 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$868,078
Profits / Employee
-$92,190
Market Cap
1.96B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BCRX News
- 1 day ago - BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million - GlobeNewsWire
- 12 days ago - BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI - GlobeNewsWire
- 15 days ago - ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewsWire
- 22 days ago - BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewsWire
- 25 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewsWire
- 4 weeks ago - BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages - GlobeNewsWire
- 4 weeks ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire